SEC Form 4 · accession 0001171843-15-000654
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Feb 3, 2015
Accepted (ET)
Feb 5, 2015 · 6:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2,F4 | Feb 3, 2015 | M | 5,144 | $4.81 | A | 10,288 | I | By Genworks Inc. |
| Common Shares | holding | — | — | — | 75,886 | I | By wife | |
| Common Shares | holding | — | — | — | 97,319 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4,F2,F3 | $4.81 | Feb 3, 2015 | M | 5,144 | D | — | May 8, 2015 | Common Shares | 5,144 | 0 | I |
Explanation of responses
- F1The common shares acquired by the Reporting Person in connection with the option exercise are subject to the terms of a Lock-up Agreement executed by the Reporting Person in favor of the underwriters of the Company's initial public offering in November 2014.
- F2The exercise price was converted from $6.07 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- F3The shares subject to the option fully vested on October 1, 2008.
- F4Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.